Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate at the benefits and harms of thyroxine for the treatment of AKI by any cause in hospitalised adult patients. The following will be addressed:

To determine whether the use of thyroxine versus placebo with or without supplemental treatment (such as furosemide, dopamine or ANP) for AKI is associated with a reduction in all-cause mortality rates.

To determine whether the use of thyroxine is associated with shorter duration of AKI, decreased need for dialysis for AKI, reduction in the rate of progression to end-stage kidney disease (ESKD).

To determine any harmful effects associated with the use of thyroxine (e.g. hypotension, arrhythmias).